CIS Pharma develops novel antibody-drug-conjugates (ADCs) based on our proprietary Cellophil® polymer platform. The Cellophil® polymers serve as a backbone that is loaded with cytotoxic drugs. The backbone together with its cargo is subsequently linked to a target-specific antibody. As a result, Cellophil® ADCs offer increased potency by linking a higher number of cytotoxic drug molecules to the antibody compared to conventional ADCs.
Conventional ADCs use covalent linkers to load cytotoxic drugs onto the antibody directly. This approach limits the number of cytotoxic drugs that are carried to the tumor cells. Nevertheless, antibody-drug-conjugates combine target-specificity of an antibody to a tumor antigen with a potent cytotoxic drug. In comparison to the administration of a cytotoxic drug alone, side effects are significantly reduced as normal cells remain unimpaired during treatment.
CIS Pharma combines biology with our expertise in chemistry and our proprietary polymer technology to create Cellophil® ADCs. The Cellophil® polymers increase the solubility of hydrophobic cytotoxic drugs that suffer from low bioavailability. Our Cellophil® ADCs have a higher drug-to-antibody-ratio (DAR) compared to conventional ADCs. The approach allows different classes of cytotoxic drugs to be linked to the backbone. A variety of target-specific agents such as antibodies, antibody fragments, aptamers and smaller homing agents can be loaded with the Cellophil® cytotoxic drug carrier. Cellophil’s® resistance to degradation may be an advantage over currently used polymers since shelf life in solution and circulation time might be increased. Cellophil® can be designed to be cleared by renal excretion after degradation of the antibody and release of the payload.